Investigating potential confounding by indication when considering the association between proton pump inhibitor use, infection, hepatic encephalopathy and mortality in hospitalised decompensated cirrhosis: a post-hoc analysis of the ATTIRE trial.
Bacterial translocation
Spontaneous bacterial peritonitis
Variceal bleeding
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
12
12
2022
revised:
25
02
2023
accepted:
08
03
2023
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Proton pump inhibitors (PPIs) are commonly prescribed to prevent and treat upper gastrointestinal ulceration and bleeding. Studies have identified increased incidence of spontaneous bacterial peritonitis and hepatic encephalopathy (HE) in cirrhosis patients taking PPIs. However, results are conflicting, and as PPIs are prescribed for variceal bleeding, a major risk factor for infection and HE, it is challenging to discern whether these associations are causal. In this post-hoc analysis of the ATTIRE trial, we pooled all patient data to investigate the effects of PPI use on clinical outcomes. ATTIRE was a multicentre, open-label, randomised trial of targeted 20% human albumin solution (HAS) daily infusions versus standard care involving 777 adults with decompensated cirrhosis hospitalised with acute complications and albumin <30 g/L. Study recruitment was between Jan 25, 2016, and June 28, 2019, at 35 hospitals across England, Scotland, and Wales. Key exclusion criteria were advanced hepatocellular carcinoma with life expectancy <8 weeks and patients receiving palliative care. In ATTIRE, patients were grouped by PPI use at trial entry. We studied infection and HE at baseline and incidence of hospital acquired infection, new onset HE, renal dysfunction and mortality. We attempted with propensity score matching to account for differences in disease severity. Overall PPI use at baseline was not associated with increased incidence of infection, renal dysfunction or mortality, but was associated with significantly increased incidence of grade III/IV HE during hospital stay ( Our real-world data from a completed randomised trial show that PPIs are widely prescribed in the UK and judicious use appears safe in patients hospitalised with decompensated cirrhosis. However, patients prescribed PPIs had fundamentally different phenotypes to those not prescribed PPIs, a form of confounding by indication, which should be strongly considered when interpreting studies and making recommendations about their use. Wellcome Trust and Department of Health and Social Care.
Sections du résumé
Background
UNASSIGNED
Proton pump inhibitors (PPIs) are commonly prescribed to prevent and treat upper gastrointestinal ulceration and bleeding. Studies have identified increased incidence of spontaneous bacterial peritonitis and hepatic encephalopathy (HE) in cirrhosis patients taking PPIs. However, results are conflicting, and as PPIs are prescribed for variceal bleeding, a major risk factor for infection and HE, it is challenging to discern whether these associations are causal.
Methods
UNASSIGNED
In this post-hoc analysis of the ATTIRE trial, we pooled all patient data to investigate the effects of PPI use on clinical outcomes. ATTIRE was a multicentre, open-label, randomised trial of targeted 20% human albumin solution (HAS) daily infusions versus standard care involving 777 adults with decompensated cirrhosis hospitalised with acute complications and albumin <30 g/L. Study recruitment was between Jan 25, 2016, and June 28, 2019, at 35 hospitals across England, Scotland, and Wales. Key exclusion criteria were advanced hepatocellular carcinoma with life expectancy <8 weeks and patients receiving palliative care. In ATTIRE, patients were grouped by PPI use at trial entry. We studied infection and HE at baseline and incidence of hospital acquired infection, new onset HE, renal dysfunction and mortality. We attempted with propensity score matching to account for differences in disease severity.
Findings
UNASSIGNED
Overall PPI use at baseline was not associated with increased incidence of infection, renal dysfunction or mortality, but was associated with significantly increased incidence of grade III/IV HE during hospital stay (
Interpretations
UNASSIGNED
Our real-world data from a completed randomised trial show that PPIs are widely prescribed in the UK and judicious use appears safe in patients hospitalised with decompensated cirrhosis. However, patients prescribed PPIs had fundamentally different phenotypes to those not prescribed PPIs, a form of confounding by indication, which should be strongly considered when interpreting studies and making recommendations about their use.
Funding
UNASSIGNED
Wellcome Trust and Department of Health and Social Care.
Identifiants
pubmed: 37090442
doi: 10.1016/j.eclinm.2023.101924
pii: S2589-5370(23)00101-3
pmc: PMC10119493
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101924Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
All authors declare no competing interests.
Références
J Hepatol. 2015 May;62(5):1056-60
pubmed: 25481567
Hepatology. 2019 Aug;70(2):640-649
pubmed: 30289992
Arch Intern Med. 2010 May 10;170(9):772-8
pubmed: 20458084
Hepatol Commun. 2019 Sep 06;3(11):1510-1519
pubmed: 31701074
Clin Transl Gastroenterol. 2022 May 01;13(5):e00476
pubmed: 35333783
N Engl J Med. 2021 Mar 4;384(9):808-817
pubmed: 33657293
Dig Liver Dis. 2016 Apr;48(4):353-9
pubmed: 26795544
Ann Gastroenterol. 2017;30(5):486-497
pubmed: 28845103
Genet Mol Res. 2015 Jul 06;14(3):7490-501
pubmed: 26214428
Clin Gastroenterol Hepatol. 2012 Apr;10(4):422-7
pubmed: 22155557
JHEP Rep. 2021 Aug 04;3(6):100332
pubmed: 34825153
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Gut Pathog. 2021 Mar 19;13(1):17
pubmed: 33741033
Med Sci Monit. 2008 Sep;14(9):CR468-72
pubmed: 18758417
Clin Gastroenterol Hepatol. 2015 Apr;13(4):753-9.e1-2
pubmed: 25130937
Gastroenterology. 2017 Jun;152(8):2076
pubmed: 28478154
J Hepatol. 2016 Mar;64(3):574-82
pubmed: 26519600
J Hepatol. 2022 Apr;76(4):959-974
pubmed: 35120736
Gastroenterology. 2017 Jan;152(1):134-141
pubmed: 27639806
Hepatology. 2017 Jan;65(1):393
pubmed: 27688049
J Clin Med. 2019 Jul 25;8(8):
pubmed: 31349746
J Gastroenterol Hepatol. 2015 Jan;30(1):147-54
pubmed: 25039465
Am J Gastroenterol. 2012 May;107(5):730-5
pubmed: 22334250
Can J Gastroenterol Hepatol. 2014 Jun;28(6):330-4
pubmed: 24945188
BMJ Open. 2018 Oct 21;8(10):e023754
pubmed: 30344180
World J Gastroenterol. 2010 Dec 14;16(46):5869-73
pubmed: 21155009
Aliment Pharmacol Ther. 2015 Mar;41(5):459-66
pubmed: 25523381
Gut. 2015 Nov;64(11):1680-704
pubmed: 25887380
PLoS One. 2014 Nov 04;9(11):e110503
pubmed: 25369194
J Gastroenterol Hepatol. 2013 Feb;28(2):235-42
pubmed: 23190338
J Hepatol. 2015 Aug;63(2):529-30
pubmed: 26015369
EClinicalMedicine. 2022 Nov 14;55:101716
pubmed: 36407574
JAMA. 2015 Oct 20;314(15):1637-8
pubmed: 26501539
Eur J Gastroenterol Hepatol. 2015 Nov;27(11):1327-36
pubmed: 26313401
J Hepatol. 2022 Sep;77(3):807-824
pubmed: 35724930
Hepatology. 2018 Oct;68(4):1498-1507
pubmed: 29091289
Hepatology. 2016 Oct;64(4):1265-72
pubmed: 27474889
JAMA. 2009 May 27;301(20):2120-8
pubmed: 19470989
Hepatology. 2019 Aug;70(2):761-762
pubmed: 30951188